Strs Ohio Sells 18,756 Shares of Natera, Inc. $NTRA

Strs Ohio lowered its position in Natera, Inc. (NASDAQ:NTRA) by 28.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 47,505 shares of the medical research company’s stock after selling 18,756 shares during the period. Strs Ohio’s holdings in Natera were worth $7,647,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC boosted its position in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its position in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth grew its stake in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in Natera during the second quarter worth approximately $298,000. Finally, GAMMA Investing LLC increased its holdings in Natera by 48.5% in the second quarter. GAMMA Investing LLC now owns 1,259 shares of the medical research company’s stock worth $213,000 after purchasing an additional 411 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider John Fesko sold 339 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $79,665.00. Following the transaction, the insider owned 177,252 shares in the company, valued at $41,654,220. This trade represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,590 shares of the company’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $373,650.00. Following the sale, the chief executive officer owned 219,150 shares of the company’s stock, valued at $51,500,250. This trade represents a 0.72% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 501,436 shares of company stock valued at $111,775,823. 5.63% of the stock is owned by company insiders.

Natera Trading Down 0.1%

NTRA opened at $241.39 on Tuesday. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36. The company has a market cap of $33.39 billion, a price-to-earnings ratio of -105.41 and a beta of 1.62. The company’s fifty day moving average price is $234.89 and its two-hundred day moving average price is $192.16.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the firm earned ($0.26) earnings per share. The company’s revenue was up 34.7% on a year-over-year basis. As a group, equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Piper Sandler upped their price objective on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, Evercore ISI raised their target price on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $245.50.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.